Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039.


Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.

Clinical trials registration: NCT01751568.

Keywords: antiretroviral therapy; drug interactions; pediatrics; rifampin; tuberculosis.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Child
  • HIV
  • HIV Infections* / drug therapy
  • Humans
  • Raltegravir Potassium / adverse effects
  • Rifampin / adverse effects
  • Tuberculosis* / complications
  • Tuberculosis* / drug therapy


  • Anti-HIV Agents
  • Raltegravir Potassium
  • Rifampin

Associated data